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Abstract. Malignant melanoma (MM) prognosis has been related to tumour thickness and clinical stage and metastasis risk has
been associated with presence of tumour cells in peripheral blood. The aim of this study was to determine the relationship
between presence of tyrosinase in peripheral blood of MM patients and their clinical prognosis. Blood samples from 58 MM
patients (stage I–IV) were analysed, using RT-PCR assay to detect tyrosinase mRNA. The results showed that positive RT-PCR
assay for tyrosinase were significantly associated with clinical status and tumour thickness. After a median follow-up of 24
months, RT-PCR results were found to be significant correlated with recurrence (p < 0.05) and clinical stage III (p < 0.05).
Separate analysis of stage III tumours to determine the prognostic value of tyrosinase presence in peripheral blood showed an
overall 24-month survival rate of 70% in the RT-PCR negative group versus 10% in the positive group (p < 0.02). These results
suggest that detection of circulating melanoma cells may be especially relevant in stage III patients, in whom RT-PCR positivity
defines a subpopulation at high risk of recurrence.
1. Introduction
The incidence rate of malignant melanoma (MM)
has increased more than that of any other malignancy
among white populations over the past 15 years [1]
The development of metastasis is the leading cause of
mortality in MM patients [2,3] Although there is no ef-
fective systemic therapy for the treatment of metastatic
MM, its early detection can improve clinical assess-
ment of the progression, metastatic potential and re-
sponse to therapy of the tumour [4]. The identifica-
tion of a biological factor that could serve to predict
the clinical progression of MM has been extensively
researched.
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Several markers of MM have been proposed to date
and the most widely used have been tyrosinase (TYR)
and its related proteins (TYRPs). Tyrosinase is a key
enzyme in melanin biosynthesis and is exclusively ex-
pressed in melanocytes and melanoma cells [5,6]. De-
tection of tyrosinase enzyme by reverse transcriptase-
polymerase chain reaction (RT-PCR) assay has been
used to detect occult melanoma cells in blood and
lymph nodes of melanoma patients [7–9]. A pivotal
study by Smith et al. [10], established the usefulness
of RT-PCR amplification of tyrosinase mRNA for de-
tecting circulating melanoma cells (CMCs). Our group
previously used this method to demonstrate presence of
CMCs in patients with melanoma at different clinical
stages [11]. There is little information on the clinical
significance of tyrosine mRNA detection in peripheral
blood of MM patients and conflicting data have been
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reported [12]. In this context, it is accepted that pres-
ence of CMCs is correlated with the clinical stage of
patients and that detection of these cells in patients with
early-stage disease may indicate a high risk of metas-
tasis and a lower probability of overall survival [13].
Recent studies described tyrosinase RT-PCR results as
a potentially useful molecular marker that may pro-
vide an early indication of therapy effectiveness [14].
However, other authors found no relationship between
positive PCR for tyrosinase and disease-free or overall
survival [15]. Therefore, the prognostic value of the
tyrosinase enzyme test remains controversial.
We report results of tyrosinase detection by RT-PCR
in peripheral blood samples from 58 MM patients in
all clinical stages (I, II, III or IV). The aim of this
study was to determine the clinical relevance of this
procedure, exploring the relationship between presence
of tyrosinase in peripheral blood of MM patients and
their clinical stage and prognosis.
2. Materials and methods
2.1. Patients
Blood samples were obtained at the Dermatology
Service of the University Hospital of Granada from
58 consecutively selected MM patients at time of pri-
mary tumour diagnosis or at relapse. Clinical stage
was classified according to AJCC recommendations:
primary cutaneous tumour (stages I and II), regional
skin or lymph node metastasis (stage III) or distant
metastatic tumour dissemination (stage IV). All stage
I–III patients were visited every 4 months during the
first 2 years after the diagnosis and every 6 months
thereafter. Follow-up sessions included clinical his-
tory, physical examination, blood cell count and bio-
chemistry allowed to carry out the disease control and
to determine the presence or the absence of relapse. In
each session simple blood was obtained to determine
the presence of CMCs by means of RT-PCR. All pa-
tients gave written consent after receiving information
on the purpose of the blood sampling. The outcome of
the PCR analyses had no influence on treatment. Blood
samples from 10 healthy subjects or patients without
melanoma were used as negative controls and analyzed
under identical conditions.
2.2. Blood collection and RNA isolation
Samples of peripheral venous blood (10 ml) from
each patient were collected in five tubes containing
ethylenediamine tetraacetic acid (EDTA), stored at
4◦C, and processed on ice within 2–4 h. After cen-
trifugation (650 x g for 5 min) the serum was collected
and treated with 45 ml diethyl pyrocarbonate-treated
water (H20-DEP) and 5 ml PBS (x l0), and centrifuged
at 650 x g for 5 min several times until a white pellet
(PBLC) was obtained. Total RNA was isolated from
the cell fraction with the IsoRNA-Fast Plus kit (Master
Diagn¤fistica, Granada, Spain) following the manufac-
turer’s instructions. Yield and purity of the RNA were
determined by ultraviolet spectroscopy.
2.3. Oligonucleotide primers
Oligonucleotide primers specific for tyrosinase were
designed according to Smith et al. [10]. The primers
5’ TTG GCA GAT TGT CTG TAG CC (sense) and
3’ AGG CAT TGT GCA TGC TGC TT (antisense)
were chosen to amplify a 284-base pair (bp) fragment
of the tyrosinase cDNA. Integrity of the RNA was de-
termined using primers 5’ ATG GAT GAT GAT ATC
GCC GCG (sense) and 3’ TCT CCA TGT CGT CCC
AGT TG (antisense) that amplified a 248-bp fragment
of β-actin [16].
2.4. RT-PCR assay
Reverse transcription (RT) was performed using 1 μg
of total RNA. First-strand cDNA was generated with
0.4 μmol/L of random hexamers, 1 mmol/L of each de-
oxynucleotide triphosphate (dNTP), 24 units of avian
myeloblastosis virus RT (Promega, Madison, Wiscon-
sin, USA) and 40 units of RNasin (Promega) in a final
volume of 20 μL of RT buffer. After incubation at 42 ◦C
for 18 min and 94◦C for 5 min (Linus Autocycler 32,
Cultek S.L. Madrid, Spain), samples were resuspended
in 80 μL of H20-DEP. For the first PCR round, 10 μL
of the RT products were diluted to 100 μL (RT buffer)
in a mixture with a final concentration of 2.0 mmol/L
MgC12, 200 μmol/L dNTP and 1 μmol/L of each ty-
rosinase primer. After a hot start (2 min at 94◦C), 2
units of Taq polymerase (Boehringer Mannheim, Ger-
many) were added, followed by 30 cycles at 94◦C for
1 min, 58◦C for 2 min, 72◦C for 3 min and 72◦C for 7
min. For the analysis, 70 μL of the reaction product was
run on a 2% agarose gel and stained with ethidium bro-
mide. The gel was viewed and photographed under ul-
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traviolet light. Specificity of the amplified product was
established by restriction enzyme digestion. Quality
of the mRNA was controlled by PCR for β-actin [16].
Lymph node metastasis from an MM patient was used
as positive control.
2.5. Statistical analysis
Two variables were included in the data analysis:
clinical stage and RT-PCR results. Clinical stage (I, II,
III and IV) was analyzed as a discrete variable. RT-PCR
results for tyrosinase mRNA were classified as positive
or negative. A two-tailed Fischer’s exact test was used
to assess the association between RT-PCR results and
clinical stage. The relationship among RT-PCR results,
clinical stage and overall survival were evaluated in all
patients. The association between RT-PCR and overall
survival was also determined within each stage [17].
Survival time was defined as the period from blood ex-
traction for PCR analysis to death or censoring. Pa-
tient survival was evaluated using the Kaplan Meier
method [18] and survival comparisons among groups
were performed using the log rank test [18]. Propor-
tional hazards analysis was used to obtain maximum
likelihood estimates of relative risks and their 95% con-
fidence intervals in univariate and multivariate analy-
ses [20,21] and to adjust for potential confounding ef-
fects. Parameters significant at the P = 0.05 level in
univariate analysis were included in a multiple propor-
tional hazards model. Software for analysis was STAT
(STATA Corp, College Station, TX, 1997).
3. Results
3.1. Patient characteristics
The study included 58 patients with MM at clinical
(AJCC) stages I–II in 14 patients, stage III in 28 patients
and stage IV in 16 patients. Patients had a median
age of 50 years (range, 24–87 years) and 56.9% were
female. Patient characteristics are reported in Table 1.
3.2. RT-PCR results, clinical stage and thickness
According to RT-PCR findings, tyrosinase was de-
tected in peripheral blood from 14 out of the 16 MM
patients (88%) with metastatic disease (stage IV); the
two remaining stage IV patients had a surgically ex-
cised isolated metastatic site with no evidence of clini-
cal disease at the time of blood extraction. CMCs were
Table 1
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RT-PCR results by stage
Total RT-PCR RT-PCR
Positive Negative
No % No %
Stage I–II 14 2 14 12 86
< 1.0 mm 10 2 8
1.1–4 mm 3 0 3
> 4 mm 1 0 1
Stage III 28 20 71 8 29
< 1.0 mm 4 1 3
1.1–4 mm 16 13 3
> 4 mm 8 6 2
Stage IV 16 14 88 2 12
also detected in the blood of two of the 14 patients at
stage I–II (14%) and in 20 of the 28 patients at stage III
(71%). All negative controls were negative for tyrosi-
nase mRNA in the RT-PCR assay. The statistical anal-
ysis showed that the RT-PCR results were significantly
associated with clinical status (p < 0.001) and tumour
thickness (p < 0.002) (Table 2) but not with primary
site or patient gender.
3.3. RT-PCR results and prognosis
After a median follow-up of 24 months (range, 3–48
months), in which RT-PCR test were realized, risk of re-
lapse was evaluated in all 58 patients. All stage I–II pa-
tients underwent complete resection of primary tumour;
50% (6/12) of stage I–II patients with negative RT-PCR
test relapsed compared with 100% of patients (2/2) with
positive PCR result. Stage III patients received postsur-
gical adjuvant chemotherapy; 85% (17/20) of RT-PCR-
positive stage III patients relapsed versus 25% (2/8)
of RT-PCR-negative patients. Neither of the two RT-
PCR-negative stage IV patients had the disease at 24
months, whereas 93% (13/14) of the RT-PCR-positive
stage IV patients relapsed (Table 3). X2 univariate anal-



















Fig. 1. Overall survival (OS) according to tyrosinase mRNA in blood in stage III patients. OS was calculated by Kaplan-Meier method.
Table 3
RT-PCR Results and Relapse in stage I–IV patients
Total Relapse Non-Relapse
No % No %
Stage I–II
RT-PCR+ 2 2 100 0 0
RT-PCR− 12 6 50 6 50
Stage III
RT-PCR+ 20 17 85 3 15
RT-PCR− 8 2 25 6 75
Stage IV
RT-PCR+ 14 13 85 3 15
RT-PCR− 8 2 25 6 75
Total
RT-PCR+ 36 32 89 4 11
RT-PCR− 22 8 36 14 64
ysis showed that RT-PCR results were significantly cor-
related with recurrence (p < 0.05) and clinical stage III
(p < 0.05). No correlation was observed between re-
currence and sex, age, histology, Breslow classification
or primary site. In a separate analysis of stage III tu-
mours to determine the prognostic value of melanoma
cell presence in peripheral blood, overall 24-month sur-
vival was 70% in the RT-PCR-negative group versus
10% in the positive group (p < 0.02) (Fig. 1). The two
significant factors according to the univariate analysis
(stage and RT-PCR status) were subjected to a multi-
variate analysis. A logistic regression model with PCR
as dependent variable and stage, histology and thick-
ness as independent variables yielded the following re-
sults, taking results for Stage I–III patients as reference:
the likelihood that a stage III patient was RT-PCR pos-
itive for tyrosinase mRNA was 15 (95% CI: 2.7–94.6)
and that a stage IV patient was positive was 42 (95%
CI: 5.1–345.1).
4. Discussion
It has recently been suggested that RT-PCR detec-
tion of tyrosinase mRNA in peripheral blood may be
useful for establishing the prognosis of patients with
MM, although published results have been inconsis-
tent. This hypothesis is based on the fact that detec-
tion of CMCs in peripheral blood indicates their mo-
bilization from the site of the primary lesion via the
peripheral blood. Some researchers reported a signif-
icant correlation between PCR positivity and clinical
outcome but others observed no such relationship [13,
22]. The present study demonstrates that tyrosinase de-
tection can be used as a molecular marker in the blood
of MM patients. This marker is correlated with clinical
stage (the most widely used MM prognostic system)
and thickness, and may be useful for establishing the
prognosis in these patients.
The detection of minimal residual disease by PCR
amplification of specific tumour cell abnormalities has
been widely used in haematologic malignancies as a
useful tool for treatment response assessment and pa-
tient follow-up [23–26]. RT-PCR was recently used to
detect malignant cells in peripheral blood of solid tu-
mour patients [9]. Tyrosinase is specifically expressed
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in melanocytes or melanoma cells. Since melanocytes
do not circulate, detection of tyrosinase mRNA in blood
indicates presence of melanoma cells. Numerous au-
thors have determined the percentage of CMC-positive
MM patients using tyrosinase as marker, but results
have ranged widely from 6% to 59% [27,28] In the
present study, 62% of MM patients showed RT-PCR
positivity, a higher percentage than in other studies with
similar sample size [29] We also found a significant as-
sociation between clinical stage of disease and RT-PCR
status. CMCs were detected in a large majority of the
patients with clinical metastasis, and in a progressively
lower proportion in PCR-detected CMCs with lower
stages of the disease. This correlation is of special rel-
evance, because clinical stage is the main clinical da-
tum used for the prognosis [29–31]. Similar findings
were published by authors using multiple marker RT-
PCR assays [32–35], who found that most stage II, III
and IV patients presented CMCs. Among the markers
used, tyrosinase showed the strongest correlation with
disease stage.
Detection of melanoma cells in peripheral blood has
been correlated with clinical disease-free period In pa-
tients with an advanced stage of the disease, a positive
test has also been related to lower patient survival [31]
and presence of visceral metastasis [36]. However,
other authors found no correlation between these vari-
ables [37,38]. Unfortunately, the heterogeneity of pub-
lished series hampers direct comparison among pub-
lished results. The present study demonstrated a statis-
tically significant correlation between recurrence and
RT-PCR results (p < 0.05). Moreover, a distinct clini-
cal evolution was observed in stage III patients accord-
ing to their RT-PCR status, with higher recurrence rates
(17/20 vs. 2/8) and worse actuarial DFS in RT-PCR-
positive patients. In fact, RT-PCR status was the only
independent prognosis factor in the multivariate analy-
sis. In contrast, our results could not show a significant
correlation between the patients prognosis of stages I–
II and the positive RT-PCR. It has been hypothesised
that cells shed from these early lesions may be able to
extravasate but lack additional properties required for
the multistep process of metastatic dissemination [39].
However, a study of a larger sample of positive patients
with a longer follow-up period is required to confirm
our findings in these patients.
5. Conclusion
In conclusion, these results demonstrate a sta-
tistically significant association between malignant
melanoma stage and RT-PCR detection of CMCs in pe-
ripheral blood. The outcome analysis showed a poorer
prognosis in the group of patients with metastastic dis-
ease and detectable CMCs. This detection may be of
special relevance in the prognosis of stage III patients,
in whom positive RT-PCR detection appears to define
a group at high risk of recurrence. Further research is
warranted to develop protocols for the use of RT-PCR
detection of CMCs in the prognosis of patients with
melanoma, in the early detection of recurrence, and in
clinical trials on the efficacy of systemic therapies.
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